secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000805928-25-000104
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q2 2025 revenue $56.7M (+18.3% YoY); raises FY guidance to $219M
-----------------------------------------------------------------------

- Q2 revenue $56.7M (+18.3% YoY); net income $0.6M ($0.01 EPS) vs loss of $1.9M ($0.04) year ago.
- Adjusted EPS $0.12 vs $0.05 YoY; adjusted EBITDA $9.3M vs $5.6M; gross margin 74.2% up from 73.8%.
- Raised FY25 revenue guidance to at least 17% growth, or $219M; reiterates gross margin 73-75% and net cash flow positive.
- FDA accepted BLA for Avance Nerve Graft; PDUFA date Sept 5, 2025; pre-licensing inspection and regulatory milestones completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592825000104/0000805928-25-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592825000104/axgn-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000805928-25-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer